Advanced Biliary Tract Cancer Clinical Trials

31 clinical trials for Advanced Biliary Tract Cancer across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer — RECRUITING · PHASE3
• A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain — RECRUITING
• A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) — RECRUITING · PHASE3
• A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer — RECRUITING · PHASE2
• GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1） — RECRUITING
• Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer — RECRUITING · PHASE2
• Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers — NOT_YET_RECRUITING · PHASE2
• Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer — NOT_YET_RECRUITING · PHASE2
• SEVILLA_A randomised, phase II trial to evaluate the efficacy of ivonescimab, a PD 1/VEGF bispecific antibody, versus FOLFOX as second line therapy for locally advanced or metastatic biliary tract cancers — TERMINATED · PHASE2
• Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. — WITHDRAWN · PHASE2
• Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment — ACTIVE_NOT_RECRUITING · PHASE2
• Combination Immunotherapy in Rare Cancers Under InvesTigation — ACTIVE_NOT_RECRUITING · PHASE2
• NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers — NOT_YET_RECRUITING · PHASE2
• NGS as the First-line Treatment in Advanced Biliary Tract Cancer — COMPLETED · PHASE2
• Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer — TERMINATED · PHASE2
• Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer — OTHER · PHASE2
• Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer — OTHER · PHASE2
• Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer — OTHER · PHASE2
• Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05) — OTHER · PHASE2
• HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC — COMPLETED · PHASE2
• IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer — OTHER · PHASE1
• Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers — OTHER · PHASE2
• Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08） — OTHER · PHASE2
• Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN) — OTHER · PHASE2
• A Phase 1/2 Study of SC-43 in Combination With Cisplatin — OTHER · PHASE1
• A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 — WITHDRAWN · PHASE3
• A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer — COMPLETED · PHASE2
• Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer — OTHER · PHASE2
• Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer — COMPLETED · PHASE1

Refine this search